Abstract
Anxiety disorders among general practice patients are the most common. We examined the efficacy and safety of
 Buspirone in patients with anxiety disorders in outpatient practice. In accordance with ICD-10, the patients were
 distributed as follows: generalized anxiety disorder – 38.7 %, panic disorder – 29 %, adjustment disorder in the form
 of mixed depressive and anxiety reaction – 32.3 %. In order to evaluate the impact of therapy the following research
 methods were used: clinical, clinical-psychopathological, psychometric (Hamilton anxiety scale (HAM-A), Spielberg-
 er-Hanin anxiety level self-evaluation scale, Shihan anxiety self-evaluation scale, Clinical Global Impression-Severity
 Scale (CGI-S), and Clinical Global Impression of Improvement (CGI-I) Scale.
 Among patients with anxiety disorders 28 people (90.3 %) have finished the study, three persons (9.7 %) dropped out
 of the study with regard to the ineffectiveness of Buspirone therapy. Analysis of the values on the HAM-A scale revealed
 statistically significant reduction in composite score by the end of day 14 (by 23.4 %, p < 0.05) and a statistically signifi-
 cant increase in differences by day 35 of therapy and reduction of scores by 51.5 % (p < 0.01). A statistically significant
 reduction (by 21.9 %, p < 0.05) of points on the Shihan anxiety scale was revealed by day 21 of therapy. Reduction of
 the mean values of the total score of reactive and personal anxiety by the Spielberger – Hanin scale was recorded from
 day 21 of therapy (p < 0.05). CGI-S scale statistically reliable reduction of patients with moderate degree of severity
 to 26.6 % (p < 0.05) and a statistically significant increase in the number of patients with mild degrees of severity by
 20 % (p < 0.05) were revealed on day 14 of therapy. On the CGI-I scale, a marked improvement (26.7 %, p < 0.05) and
 a slight improvement (33.3 %, p < 0.05) is achieved by day 14 of therapy. Undesirable effects in the form of motor co-
 ordination disturbance, drowsiness, dizziness leveled during the therapy and did not require additional prescriptions
 for their correction. Buspirone can be recommended as an effective anxiolytic drug with safe portability profile for the
 treatment of anxiety disorders.
Highlights
Среди пациентов общей практики тревожные расстройства относятся к наиболее распространённым
We examined the efficacy and safety of Buspirone in patients with anxiety disorders in outpatient practice
In order to evaluate the impact of therapy the following research methods were used: clinical, clinical-psychopathological, psychometric (Hamilton anxiety scale (HAM-А), Spielberger-Hanin anxiety level self-evaluation scale, Shihan anxiety self-evaluation scale, Clinical Global Impression-Severity Scale (CGI-S), and Clinical Global Impression of Improvement (CGI-I) Scale
Summary
Иркутская государственная медицинская академия последипломного образования – филиал ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России Изучена эффективность и безопасность буспирона у пациентов с различными проявлениями тревожных расстройств. Положительная динамика на 2–3-й неделе приёма буспирона включала редукцию диссомнических расстройств, суетливости, напряжения в мышцах, уменьшение утомляемости, повышение работоспособности в повседневной и профессиональной деятельности. На 4–5-й неделе терапии выявлены уменьшение проявлений вегетативной гиперактивности, урежение панических атак, дезактуализация навязчивых тревожных опасений неипохондрического и ипохондрического содержания, сенсорных расстройств, преходящих эпизодов аффективной лабильности. По шкале тревоги Гамильтона выявлена статистически значимая положительная динамика на 14-й день приёма буспирона в виде снижения баллов по показателям психической и соматической тревоги; статистически значимая редукция суммарного балла по шкалам тревоги Шихана и Спилберга – Ханина зарегистрирована на 21-й день терапии. Буспирон является эффективным и безопасным препаратом у пациентов с тревожными расстройствами в общей практике. Буспирон может быть рекомендован в качестве эффективного современного анксиолитического препарата с безопасным профилем переносимости для лечения тревожных расстройств
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
